Epidemiology of hepetitis C infection, ERHA/HSE Eastern region by Meara, MO et al.
Introduction
Hepatitis C Virus (HCV), a major public health threat, is endemic to most parts of the world. The World Health
Organisation has estimated that the current prevalence of HCV infection is 2% representing 123 million cases worldwide.1
Whilst the epidemiology of hepatitis A and B is well established, data about HCV are limited. Many aspects of this
disease remain unclear, including its prevalence, natural course of infection and the socio−economic burden of infection
worldwide. Risk factors strongly associated with HCV infection are intravenous drug use (IDU), receipt of infected
blood products, use of inadequately sterilised medical equipment, high−risk sexual behaviours, body piercing and
tattooing.1,2 Perinatal transmission has been reported, but is not very efficient except in mothers with HIV
co−infection.3
Of those exposed to HCV, it is estimated that the majority will become chronic carriers with an increased risk of
developing cirrhosis and hepatocellular carcinoma. 2 In Europe it is estimated that 8.9 million people have been
infected, with the majority of cases diagnosed in those with a history of IDU.
Blood donations were not routinely tested for HCV prior to 1991.The awareness of HCV infection in the Irish population
was raised when women who received infected anti−D immunoglobulin after pregnancy in 1977 and 1991 were found through a
lookback exercise to have been infected by HCV. A Tribunal of Inquiry was set up to investigate the practices and
procedures that lead to anti−D immunoglobulin becoming infected with HCV . This tribunal reported in 1997 (The Finlay
Report).4 A subsequent investigation of haemophiliacs who became infected with HIV and HCV having received contaminated
blood products was addressed by the Lindsay Report in 2002.5
Despite this raised awareness of HCV infection in the 1990s, it was only on January 1st 2004 following an Amendment to
the Infectious Disease Regulations of 1981 that HCV became statutorily notifiable in its own right6. The Amendment
established a revised list of notifiable diseases, and included for the first time HCV as a disease entity. HCV is now
notifiable by laboratories or clinicians to the relevant Medical Officer for Health.
Prior to 2004, only hepatitis A and hepatitis B were notifiable as distinct types of hepatitis. A third category
notifiable under the Infectious Diseases Regulations 1981 was â€œviral hepatitis unspecifiedâ€. The vast majority of
cases notified under this heading in recent years were thought to be due to infection with HCV.
Surveillance data for infectious diseases are collated nationally by the Health Protection Surveillance Centre (HPSC).
The HPSC publishes quarterly and annual reports on HCV notifications which are available on their website www.hpsc.ie.
The prevalence of HCV infection in the general Irish population is unknown. Prevalence studies have been undertaken in
selected study populations, i.e. blood donors7, IDU8−10 antenatal screening11 and studies within the prison services12,13.
These data on diverse populations show that the prevalence of HCV varies depending on the populations studied, ranging
from 0.02% of new blood donors to 50−80% of IDUâ€™s.
We describe notifications for the Eastern Regional Health Authority (ERHA), comprising counties Dublin, Kildare and
Wicklow for the period 2004 and 2005. On the 1st of January 2005 the Health Service Executive (HSE) was established to
take over the management of the Irish Health Services and the ERHA was renamed the HSE−Eastern Region. We describe the
epidemiology of HCV over this time period, have assigned risk status where possible and comment on difficulties with the
notification process.
Methodology
All cases of notified infectious disease are entered on the general infectious disease database maintained in the
Department of Public Health. Cases of HCV were abstracted by the authors
Where the notifying physician was identifiable (general practitioner or hospital consultant), contact was made by
letter to gather enhanced data on risk factors. Only drug use was identified by this method. One of the authors(JB)
manages the central treatment list which is a database of persons in receipt of methadone treatment for opiate use. It
was possible to examine the methadone database to determine how many of the HCV notifications occurred in opiate users.
Results
A total of 2,014 cases of HCV were notified to the Department of Public Health, (2004, 941 cases, 2005 1,073 cases).
There is no seasonal trend to HCV notifications. The mean number of notifications per month was 83 (Range 29−116) (Fig
1).
Fig 1 Number of HCV Cases by Month of
Notification 2004 and 2005
There were a higher number of cases in males with 1,269 cases notified, compared to 714 cases in females.
Modal age band of notification was in the 25−29 year age group with 331 (16.4%) of male cases and 198 (9.8%) of female
cases occurring in this age group (Fig 2). Thirty cases (1.5%)were notified in children under the age of 15 years (Fig
2).
Fig 2 Age and Gender distribution of
HCV cases Notified 2004 and 2005
Table 1 outlines the age specific rates per 100,000 population, for cases notified in 2004 and 2005 combined.
Table 1 Age Specific rates (per 100,000) by sex for notified cases of HCV in ERHA 2004 and 2005
Female Male
Age group Number of cases Rate per 100,000 Number of cases Rate per 100,000
0−4 10 21.2 8 17.1
5−9 1 2.3 0 0
10−14 7 15.1 4 8.2
0−14 18 13.2 12 8.4
15−19 12 22.8 10 18.4
20−24 138 197.5 169 250.7
25−29 198 291.1 331 505.4
30−34 139 229.5 258 433.2
35−39 96 176.4 168 323.0
40−44 42 85.2 154 327.7
45−49 22 54.5 84 201.5
50−54 13 32.1 44 114.0
55−60 9 26.4 11 33.6
60−64 6 22.2 6 23.6
65−69 2 8.6 1 4.9
75+ 6 12.3 7 21.8
Gathering information on risk factors was more problematic than descriptive epidemiology. By examining the methadone
database it was possible to identify that 1247 (61.9%) patients had a history of opiate use. The source of notification
for the remaining 767 (38.1%) patients is given in table 2. While it is possible to assume that drug users would be over
represented in some of these services no definitive risk category can be assigned.
Table 2 Source of Notification of those with HCV infection where risk category is unknown
Number % of Total Cases
General Hospital 345 17.1
Antenatal 71 3.5
General Practitioner 67 3.3
Asylum Seeking Service 35 1.7
Women's Health 19 0.9
Prison 16 0.8
No clinician named on notification form 214 10.6
Total 767
1
Two hundred and twenty one cases (10.9%) were notified on the basis of initial only− and in addition in 214 cases
(10.6%) (Table 2) a notifying source (general practitioner or hospital) was not identifiable.
Discussion
Our paper highlights the importance of statutory notification. Prior to 2004 the main epidemiological information in
this country came from a variety of cross sectional surveys carried out among drug users and prisoners and one incidence
study carried out in drug users.8,−13 Information was in the public domain as a result of Tribunals of Inquiry into the
transmission of HCV through blood and blood products4,5.
While we are now in a position to begin to construct a picture of HCV in Ireland challenges remain. Complete
notification will help i.e. a patientâ€™s full name and an identifiable notifying clinician. Without this information it
is difficult to assign risk category.
Enhanced surveillance offers one way of improving our knowledge of risk category. This will require notifying clinicians
to make a judgement on how they believe their patient acquired their infection. If this is done our information will be
of a higher quality. . There will still be questions that cannot be answered by a routine surveillance system. Planned
epidemiological studies will be required to enable us to know the true extent and causes of HCV in Ireland. Given that
so much controversy has surrounded the transmission of HCV in Ireland these studies should be funded. A start would be a
national prevalence study, as was done for hepatitis B some years ago14.
A start has been made in describing the epidemiology of HCV in a region of Ireland. Some improvements in the quality of
notifications is required It will also be necessary to move to a higher level of epidemiological enquiry in order to
understand better transmission patterns, so that service responses can be improved.
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